Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Avicanna Inc. (AVCNF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2777+0.0067 (+2.47%)
At close: 11:47AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2710
Open0.2611
BidN/A x N/A
AskN/A x N/A
Day's Range0.2611 - 0.2777
52 Week Range0.1670 - 1.2400
Volume1,401
Avg. Volume12,198
Market Cap12.735M
Beta (5Y Monthly)2.18
PE Ratio (TTM)N/A
EPS (TTM)-0.4750
Earnings DateNov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Avicanna Reports Q1 2022 Financial Statement and Management Change

    NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, May 12, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce the filin

  • GlobeNewswire

    Mycotopia Therapies Inc. Update on Ei.Ventures and Strategic Investments

    MIAMI, May 09, 2022 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. (OTC Pink: TPIA), a biopharma company focused on research, technology, and the development of medical psychedelics, and Ei.Ventures Inc., a technology company empowering mental wellness through psychoactive compounds, nutraceuticals and web 3.0, are pleased to announce several strategic investments to advance the combined company's business plan. Ei.Ventures completed its Regulation A+ financing round on March 22, 2022 after announ

  • GlobeNewswire

    Avicanna Announces Closing of Strategic Private Placement

    NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS TORONTO, May 06, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it h

Advertisement
Advertisement